BC025816 Activators encompass a range of chemical compounds that indirectly enhance the functional activity of BC025816 through various signaling pathways. Forskolin, by raising intracellular cAMP levels, indirectly augments BC025816's activity through cAMP-dependent protein kinase A (PKA) activation, which may phosphorylate substrates including BC025816. Similarly, PMA as a PKC activator and Ionomycin by increasing calcium levels can facilitate the activation of BC025816 if it is a part of or regulated by PKC or calcium-dependent signaling pathways. Compounds like 8-Bromo-cAMP and Dibutyryl cAMP, which are analogs of cAMP, engage the same pathways potentially enhancing BC025816 activity, assuming it is cAMP-responsive. EGCG, through its inhibitory action on certain protein kinases, might relieve inhibitory phosphorylations on BC025816, thereby activating it.
Additionally, LY294002 and U0126, by inhibiting PI3K and MEK1/2 respectively, may modify downstream signaling, potentially leading to the activation of BC025816 if it is a part of the PI3K-Akt or ERK/MAPK signaling pathways. SB203580 acts as a p38 MAPK inhibitor, potentially redirecting signaling to alternative pathways that could involve BC025816. Thapsigargin and Sphingosine-1-phosphate, by disrupting calcium homeostasis and modulating sphingolipid"Naming instructions" were not provided. Please provide the specific "protein name" and "gene name" for accurate completion of the task. BC024814 activators are a specialized group of compounds that are characterized by their ability to enhance the activity of the molecular target identified by the code BC024814. The discovery and development of these activators typically commence with a high-throughput screening (HTS) protocol. This involves the application of large libraries of chemical entities to an assay system designed to detect the activation of BC024814. These assays are sensitive and quantitative, often relying on fluorescent or luminescent readouts that can directly correlate with the activation state of BC024814.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which may phosphorylate BC025816 or related proteins, leading to its activation if BC025816 is part of the PKC signaling cascade. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin increases intracellular calcium levels, potentially activating calcium-dependent enzymes that could phosphorylate and activate BC025816. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
This cAMP analog activates cAMP-dependent pathways, potentially enhancing BC025816 activity if it is cAMP-responsive. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG inhibits certain protein kinases, potentially reducing inhibitory phosphorylations and thus activating BC025816 if it is usually kept inactive by such phosphorylations. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
This PI3K inhibitor could alter downstream signaling pathways, resulting in the activation of BC025816 if it is negatively regulated by PI3K-dependent pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, which may shift signaling equilibria and activate BC025816 if it is part of the ERK/MAPK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This p38 MAPK inhibitor may redirect signaling towards alternative pathways, potentially activating BC025816 if it is part of those pathways. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin disrupts calcium homeostasis, potentially activating BC025816 through calcium-dependent signaling mechanisms. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
By modulating sphingolipid signaling, this compound could activate BC025816 if it is involved in pathways responsive to sphingolipids. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
A PKC inhibitor that, through altering PKC-mediated pathways, could indirectly lead to the activation of BC025816 if it is downstream of PKC. | ||||||